MedPath

Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

Phase 3
Completed
Conditions
Colonoscopy
Interventions
Drug: Bowel Prep
Registration Number
NCT04446312
Lead Sponsor
Braintree Laboratories
Brief Summary

The purpose of this study is to compare the safety and efficacy of BLI4900 bowel preparation to an FDA-approved control as 2-day, split-dose bowel preparations prior to colonoscopy in adult patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.
  • 18 to 85 years of age (inclusive)
  • If female, and of child-bearing potential, is using an acceptable form of birth control.
  • Negative serum pregnancy test at screening, if applicable
  • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study
Exclusion Criteria
  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastroparesis, gastric retention, bowel perforation, toxic colitis or megacolon.
  • Subjects with inflammatory bowel disease who have a history of any bowel resection (small intestine or colon), suspected active inflammation, or symptoms suggestive of obstruction or known bowel stricture.
  • Subjects who had previous significant gastrointestinal surgeries.
  • Subjects who have regularly used laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation
  • Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.
  • Subjects taking diuretics, anti-hypertensive medications, including angiotensin converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs), or chronic NSAIDs, that have not been stable for 30 days.
  • Subjects with uncontrolled hypertension.
  • Subjects taking antibiotics within 7 days of colonoscopy.
  • Subjects with severe renal, hepatic or cardiac insufficiency.
  • Subjects with an abnormal and clinically significant physical examination or ECG finding at Visit 1.
  • Subjects undergoing insulin therapy for any indication.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects undergoing colonoscopy for foreign body removal and/or decompression.
  • Subjects taking tricyclic antidepressants.
  • Subjects using drugs of abuse, including abused prescription medications.
  • Subjects who are withdrawing from alcohol or benzodiazepines.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BLI4900Bowel PrepExperimental bowel preparation solution for oral ingestion
FDA Approved ControlBowel PrepFDA approved bowel preparation solution for oral ingestion
Primary Outcome Measures
NameTimeMethod
Proportion of Subjects With Successful Bowel Preparation2 days

Successful bowel preparation is defined as a preparation rated as Excellent or Good by the blinded endoscopist on a 4 point scale (Excellent, Good, Fair, Poor).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (34)

302 Research Site 5

🇺🇸

Oak Lawn, Illinois, United States

302 Research Site 39

🇺🇸

Brooklyn, New York, United States

302 Research Site 28

🇺🇸

Miami, Florida, United States

302 Research Site 29

🇺🇸

Miami, Florida, United States

302 Research Site 30

🇺🇸

Miami, Florida, United States

302 Research Site 21

🇺🇸

Houston, Texas, United States

302 Research Site 33

🇺🇸

Kingsport, Tennessee, United States

302 Research Site 26

🇺🇸

Mandeville, Louisiana, United States

302 Research Site 36

🇺🇸

Monroe, Louisiana, United States

302 Research Site 34

🇺🇸

Baton Rouge, Louisiana, United States

302 Research Site 11

🇺🇸

North Little Rock, Arkansas, United States

302 Research Site 22

🇺🇸

Bristol, Connecticut, United States

302 Research Site 2

🇺🇸

Tucson, Arizona, United States

302 Research Site 23

🇺🇸

Jackson, Tennessee, United States

302 Research Site 10

🇺🇸

Little Rock, Arkansas, United States

302 Research Site 9

🇺🇸

Chula Vista, California, United States

302 Research Site 31

🇺🇸

Los Angeles, California, United States

302 Research Site 17

🇺🇸

Fleming Island, Florida, United States

302 Research Site 3

🇺🇸

Inverness, Florida, United States

302 Research Site 14

🇺🇸

Jacksonville, Florida, United States

302 Research Site 38

🇺🇸

Palm Harbor, Florida, United States

302 Research Site 16

🇺🇸

Hagerstown, Maryland, United States

302 Research Site 37

🇺🇸

Great Neck, New York, United States

302 Research Site 25

🇺🇸

High Point, North Carolina, United States

302 Research Site 8

🇺🇸

Asheville, North Carolina, United States

302 Research Site 1

🇺🇸

Raleigh, North Carolina, United States

302 Research Site 18

🇺🇸

Cincinnati, Ohio, United States

302 Research Site 13

🇺🇸

Wilmington, North Carolina, United States

302 Research Site 32

🇺🇸

Cedar Park, Texas, United States

302 Research Site 27

🇺🇸

Webster, Texas, United States

302 Research Site 35

🇺🇸

Southlake, Texas, United States

302 Research Site 7

🇺🇸

Bellevue, Washington, United States

302 Research Site 4

🇺🇸

Fairfax, Virginia, United States

302 Research Site 6

🇺🇸

Charlottesville, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath